Unknown PHASE1 INTERVENTIONAL 10-arm NCT06047184

Phase I Study of BEBT-209 in Women With Advanced Breast Cancer

A Phase I, Open, Multicenter Study of BEBT-209 in Women With Advanced Breast Cancer

Sponsor: BeBetter Med Inc

Interventions BEBT-209 capsules Fulvestrant Letrozole tablets

Updated 4 times since 2023 Last updated: Sep 14, 2023 Started: Jul 15, 2019 Primary completion: Oct 20, 2023 Completion: Nov 20, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced Breast Cancer and is currently ongoing. BeBetter Med Inc leads this study, which shows 4 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Oct 2025 — Present [monthly]

Unknown PHASE1

Status: Active Not Recruiting → Unknown
Sep 2024 — Oct 2025 [monthly]

Active Not Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1
Oct 2023 — Jul 2024 [monthly]

Active Not Recruiting PHASE1

First recorded

Jul 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BeBetter Med Inc
Hunan Cancer Hospital
Xiangya Hospital of Central South University

Data source: BeBetter Med Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Changsha, China